Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9431365 | 0.83 | POLB (0.35) | HTR2CHTR2BPOLBTAAR1CYP2D6 | |
| SCHEMBL24105706 | 0.80 | POLB (0.33) | HTR2CHTR2BPOLBTAAR1CYP2D6 | |
| SCHEMBL24132563 | 0.80 | NFE2L2 (0.33) | HTR2CHTR2BPOLBTAAR1CYP2D6 | |
| SCHEMBL24105721 | 0.76 | — | — | |
| SCHEMBL5094518 | 0.76 | HTR2C (0.51) | HTR2CHTR2BTAAR1CYP2D6KDM1A | |
| SCHEMBL30515523 | 0.76 | HTR2C (0.51) | HTR2CHTR2BTAAR1CYP2D6KDM1A | |
| SCHEMBL8251752 | 0.75 | KDM1A (0.47) | HTR2CHTR2BKDM1AKDM1B | |
| SCHEMBL14653946 | 0.73 | CYP2D6 (0.47) | HTR2CHTR2BTAAR1CYP2D6KDM1A | |
| SCHEMBL24105771 | 0.73 | HTR2C (0.38) | HTR2CHTR2BTAAR1CYP2D6KDM1A | |
| SCHEMBL193995 | 0.72 | NFE2L2 (0.46) | POLBNFE2L2IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115836076-B | Compounds as CAV1.2 activators | 诺华股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-115698017-B | Methyl 2-methyl-5-oxo-1, 4,5, 7-tetrahydrofurano [3,4-b ] pyridine-3-carboxylate compounds as CAV1.2 activators | 诺华股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| EP-4165047-A1 | METHYL 2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATES AND METHYL 2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATES AS CAV1.2 ACTIVATORS | Novartis AG (CH) | 2023-04-19 | — | — | EP | disclosed |
| CN-115836076-A | Methyl 2- (fluoromethyl) -5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta [ B ] pyridine-3-carboxylate and methyl 2- (fluoromethyl) -5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro [3,4-B ] pyridine-3-carboxylate as CAV1.2 activators | 诺华股份有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-115698017-A | Methyl 2-methyl-5-oxo-1, 4,5, 7-tetrahydrofuro [3,4-b ] pyridine-3-carboxylate compounds as CAV1.2 activators | 诺华股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021255608-A1 | METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4- B]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | NOVARTIS AG (CH) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021253180-A1 | METHYL (R) -2- (FLUOROMETHYL) -5-OXO-4-PHENYL-4, 5, 6, 7-TETRAHYDRO-1H-CYCLOPENTA [B] PYRIDINE-3-CARBOXYLATE AND METHYL (R) -2- (FLUOROMETHYL) -5-OXO-4-PHENYL-1, 4, 5, 7-TETRAHYDROFURO [3, 4-B] PYRIDINE-3-CARBOXYLATE AS CAV1.2 ACTIVATORS | NOVARTIS AG (CH) | 2021-12-23 | — | — | WO | disclosed |
| US-20210395261-A1 | METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATE AND METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATE AS CAV1.2 ACTIVATORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-12-23 | — | — | US | disclosed |
| WO-2021255607-A1 | METHYL 2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATES AND METHYL 2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATES AS CAV1.2 ACTIVATORS | NOVARTIS AG (CH) | 2021-12-23 | — | — | WO | disclosed |
| US-20210387995-A1 | METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4-b]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395261-A1 | METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATE AND METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATE AS CAV1.2 ACTIVATORS | CACNA1D, CACNA1B, CACNA1S | HTR2C 134/4885HTR2B 113/4885POLB 3208/4885 |
| US-20210387995-A1 | METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4-b]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS | CACNA1D, CACNA1I, CACNA1S | HTR2C 287/4885HTR2B 333/4885POLB 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.